Literature DB >> 1033162

Complications of argon laser retinal photocoagulation: a five-year study.

H L Little.   

Abstract

The operator must become familiar with the dangers involved with argon laser photocoagulation. The hazards in the use of the argon laser slit-lamp photocoagulator derive from the same properties of the instrument that make it advantageous for the treatment of retinal vascular diseases: the wavelengths are highly absorbed by blood, and the beam can be focused to a small diameter. Of course complications can be avoided entirely by using applications so light the virtually no effect is obtained; but such an approach, although safe, cannot be therapeutic.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1033162

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN: 0020-8167


  4 in total

1.  Role of vascular endothelial growth factor in the breakdown of the blood-aqueous barrier after retinal laser photocoagulation in pigmented rabbits.

Authors:  Muh-Shy Chen; Ching-Chung Chang; Chang-Ping Lin; Peng-Chen Wang; Li-Rong Lin; Ping-Kang Hou; Tzyy-Chang Ho
Journal:  J Ocul Pharmacol Ther       Date:  2011-10-19       Impact factor: 2.671

2.  Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients.

Authors:  Young Gun Park; Seungbum Kang; Minhee Kim; Nari Yoo; Young Jung Roh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-18       Impact factor: 3.117

3.  Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years.

Authors:  Yang Jae Kim; Si Yeol Kim; Seungmin Ha; Daruchi Moon; San Seong; Oh Woong Kwon; Han Sang Park
Journal:  Eye (Lond)       Date:  2019-01-04       Impact factor: 3.775

4.  Evaluation of the choroidal vascularity index after subthreshold yellow laser treatment in the patients with chronic central serous chorioretinopathy.

Authors:  Sema Tamer Kaderli; Aylin Karalezli; Ahmet Kaderli; Simay Can Taskin; Sabahattin Sul
Journal:  Eye (Lond)       Date:  2022-05-13       Impact factor: 4.456

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.